This phase I trial is to find out the best dose.possible benefits and/or side effects of engineered natural killer(NK) cells containingdeleted TGF-betaR2 and NR3C1 (cord blood [CBJ- NK-TGF-betaR2-/NR3C1 -) in treating patients with glioblastoma that has come back (recurrent). CB- K- TGF-betaR2- /NR3C1 -cells are genetically changed immune cells that may help to control the disease. Here, NR3C1 is linked to glioblastoma.